Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 8, Issue 15

August 13 2024

In this Issue

INSIDE BLOOD ADVANCES
ADVANCES VIEWPOINT
CLINICAL TRIALS AND OBSERVATIONS
GENE THERAPY
HEALTH SERVICES AND OUTCOMES
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY AND IMMUNOTHERAPY
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
PLASMA CELL DISORDERS
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
RESEARCH LETTERS
COMMENTARY
ERRATUM

INSIDE BLOOD ADVANCES

Donor safety confirmed

Jeff Szer

View Articletitled, Donor safety confirmed

This differentiation block will not stand, man: ivosidenib for MDS
Clinical Trials & Observations

Ryan J. Beechinor,Brian A. Jonas

View Articletitled, This differentiation block will not stand, man: ivosidenib for MDS

Second chances for secondary AML

Jacob S. Appelbaum,Frederick R. Appelbaum,Mary-Elizabeth Percival

View Articletitled, Second chances for secondary AML

ADVANCES VIEWPOINT

Need for consensus on primary end points and efficacy definitions in trials for adult acute lymphoblastic leukemia
Clinical Trials & Observations

Matthew J. Wieduwilt

View Articletitled, Need for consensus on primary end points and efficacy definitions in trials for adult acute lymphoblastic leukemia

CLINICAL TRIALS AND OBSERVATIONS

Determinants of cognitive dysfunction in adults with sickle cell–related stroke or suspected neurological morbidity
Clinical Trials & Observations

Despina Messimeris,Hugo Bismuth,Corentin Provost,Clémentine Emaer,Nicolas Mélé,Robert Kitenge,Jean-Benoit Arlet,Laure Joseph,Brigitte Ranque,Pablo Bartolucci,Pauline Narme,David Calvet

View Articletitled, Determinants of cognitive dysfunction in adults with sickle cell–related stroke or suspected neurological morbidity

Supplemental data

Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19
Clinical Trials & Observations

Dolores Grosso,John L. Wagner,Allyson O’Connor,Kaitlyn Keck,Yanping Huang,Zi-Xuan Wang,Hilary Mehler,Benjamin Leiby,Phyllis Flomenberg,Usama Gergis,Neda Nikbakht,Michael Morris,Julie Karp,Alexis Peedin,Neal Flomenberg

View Articletitled, Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19

Supplemental data

Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim
Clinical Trials & Observations

Heather E. Stefanski,Michelle Kuxhausen,Stephanie Bo-Subait,Hati Kobusingye,Deborah Mattila,Jennifer Schenfeld,Darcie Sandschafer,Cisio De Oliveira Brandao,Linda J. Burns,Bronwen E. Shaw,Michael A. Pulsipher,John P. Miller,Steven M. Devine

View Articletitled, Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim

Supplemental data

Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
Clinical Trials & Observations

Courtney D. DiNardo,Gail J. Roboz,Justin M. Watts,Yazan F. Madanat,Gabrielle T. Prince,Praneeth Baratam,Stéphane de Botton,Anthony Stein,James M. Foran,Martha L. Arellano,David A. Sallman,Mohammad Hossain,Dylan M. Marchione,Xiaofei Bai,Prapti A. Patel,Stephanie M. Kapsalis,Guillermo Garcia-Manero,Amir T. Fathi

View Articletitled, Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome

Supplemental data

GENE THERAPY

A simplified G-CSF–free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model

Chang Li,Anna K. Anderson,Peter Ruminski,Michael Rettig,Darja Karpova,Hans-Peter Kiem,John F. DiPersio,André Lieber

View Articletitled, A simplified G-CSF–free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model

Supplemental data

HEALTH SERVICES AND OUTCOMES

Modified Delphi panel consensus recommendations for management of severe aplastic anemia

Daria V. Babushok,Amy E. DeZern,Carlos M. de Castro,Zora R. Rogers,David Beenhouwer,Michael S. Broder,Suzanne R. Fanning,Sarah N. Gibbs,Rabi Hanna,Jaroslaw P. Maciejewski,Bart L. Scott,Srinivas K. Tantravahi,Marcin W. Wlodarski,Irina Yermilov,Bhumika J. Patel

View Articletitled, Modified Delphi panel consensus recommendations for management of severe aplastic anemia

Supplemental data

HEMATOPOIESIS AND STEM CELLS

Neurobeachin regulates hematopoietic progenitor differentiation and survival by modulating Notch activity

Miguel Ganuza,Antonio Morales-Hernández,Alanna Van Huizen,Ashley Chabot,Trent Hall,Claire Caprio,David Finkelstein,Manfred W. Kilimann,Shannon McKinney-Freeman

View Articletitled, Neurobeachin regulates hematopoietic progenitor differentiation and survival by modulating Notch activity

Supplemental data

Chronic TNF in the aging microenvironment exacerbates Tet2 loss-of-function myeloid expansion

Candice Quin,Erica N. DeJong,Amy J. M. McNaughton,Marco M. Buttigieg,Salman Basrai,Sagi Abelson,Maggie J. Larché,Michael J. Rauh,Dawn M. E. Bowdish

View Articletitled, Chronic TNF in the aging microenvironment exacerbates Tet2 loss-of-function myeloid expansion

Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma
Clinical Trials & Observations

Cody A. Ramirez,Michelle Becker-Hapak,Kartik Singhal,David A. Russler-Germain,Felix Frenkel,Erica K. Barnell,Ethan D. McClain,Sweta Desai,Timothy Schappe,Onyinyechi C. Onyeador,Olga Kudryashova,Vladislav Belousov,Alexander Bagaev,Elena Ocheredko,Susanna Kiwala,Jasreet Hundal,Zachary L. Skidmore,Marcus P. Watkins,Thomas B. Mooney,Jason R. Walker,Kilannin Krysiak,Felicia Gomez,Catrina C. Fronick,Robert S. Fulton,Robert D. Schreiber,Neha Mehta-Shah,Amanda F. Cashen,Brad S. Kahl,Ravshan Ataullakhanov,Nancy L. Bartlett,Malachi Griffith,Obi L. Griffith,Todd A. Fehniger

View Articletitled, Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma

Supplemental data

Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies

Zhengyuan Dong,L. Elizabeth Budde,Elizabeth Oh,Szymon Szymura,Aaron Anderson,Marissa Del Real,Soung-chul Cha,Stephen J. Forman,Larry W. Kwak,Xiuli Wang

View Articletitled, Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies

Supplemental data

Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma
Clinical Trials & Observations

Shlomit Kfir-Erenfeld,Nathalie Asherie,Eyal Lebel,Vladimir Vainstein,Miri Assayag,Tatyana Dubnikov Sharon,Sigal Grisariu,Batia Avni,Shlomo Elias,Rivka Alexander-Shani,Nomi Bessig,Alaa Shehadeh,Aseel Ishtay,Veronica Zelmanovich,Eran Zimran,Marjorie Pick,Ilan Roziner,Ron S. Kenett,Yael Cohen,Irit Avivi,Cyrille J. Cohen,Moshe E. Gatt,Polina Stepensky

View Articletitled, Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma

Supplemental data

CG001, a C3b-targeted complement inhibitor, blocks 3 complement pathways: development and preclinical evaluation

Ling Li,Peipei Ding,Yanrong Dong,Shupei Shen,Xinyue Lv,Jie Yu,Luying Li,Jianfeng Chen,Pilin Wang,Bing Han,Ting Xu,Weiguo Hu

View Articletitled, CG001, a C3b-targeted complement inhibitor, blocks 3 complement pathways: development and preclinical evaluation

Supplemental data

LYMPHOID NEOPLASIA

Inference of genomic lesions from single-cell RNA-seq in myeloma improves functional intraclonal and interclonal analysis

Francesca Lazzaroni,Antonio Matera,Alessio Marella,Akihiro Maeda,Giancarlo Castellano,Alfredo Marchetti,Sonia Fabris,Stefania Pioggia,Ilaria Silvestris,Domenica Ronchetti,Silvia Lonati,Giuseppina Fabbiano,Valentina Traini,Elisa Taiana,Laura Porretti,Federico Colombo,Claudio De Magistris,Margherita Scopetti,Marzia Barbieri,Loredana Pettine,Federica Torricelli,Antonino Neri,Francesco Passamonti,Marta Lionetti,Matteo Claudio Da Vià,Niccolò Bolli

View Articletitled, Inference of genomic lesions from single-cell RNA-seq in myeloma improves functional intraclonal and interclonal analysis

Supplemental data

Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies

Shuhui Deng,Sanika Derebail,Vera Joy Weiler,Jessica Fong Ng,Elena Maroto-Martin,Madhumouli Chatterjee,Giulia Giorgetti,Chandraditya Chakraborty,Poonam Kalhotra,Ting Du,Yao Yao,Rao Prabhala,Masood Shammas,Annamaria Gulla,Anil Aktas Samur,Mehmet Kemal Samur,Lugui Qiu,Kenneth C. Anderson,Mariateresa Fulciniti,Nikhil C. Munshi

View Articletitled, Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies

Supplemental data

MYELOID NEOPLASIA

Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia

Tejashree Joglekar,Alexander Chin,Alin Voskanian-Kordi,Seungchul Baek,Azim Raja,Apurv Rege,Weiliang Huang,Maureen Kane,Marikki Laiho,Thomas R. Webb,Xiaoxuan Fan,Michael Rubenstein,Charles J. Bieberich,Xiang Li

View Articletitled, Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia

Supplemental data

The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts

In Young Choi,Jonathan P. Ling,Jian Zhang,Eric Helmenstine,Wencke Walter,Panagiotis Tsakiroglou,Riley E. Bergman,Céline Philippe,James L. Manley,Kevin Rouault-Pierre,Bing Li,Daniel H. Wiseman,Kiran Batta,Madhu Ouseph,Elsa Bernard,Benjamin Dubner,Xiao Li,Torsten Haferlach,Anna Koget,Salman Fazal,Tania Jain,Christopher D. Gocke,Amy E. DeZern,William Brian Dalton

View Articletitled, The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts

Supplemental data

Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT

Arnon Nagler,Myriam Labopin,Johanna Tischer,Anna Maria Raiola,Desiree Kunadt,Jan Vydra,Didier Blaise,Patrizia Chiusolo,Renato Fanin,Julia Winkler,Edouard Forcade,Gwendolyn Van Gorkom,Fabio Ciceri,Mohamad Mohty

View Articletitled, Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT

Supplemental data

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

A JAGN1-associated severe congenital neutropenia zebrafish model revealed an altered G-CSFR signaling and UPR activation

Larissa Doll,Karl Welte,Julia Skokowa,Baubak Bajoghli

View Articletitled, A JAGN1-associated severe congenital neutropenia zebrafish model revealed an altered G-CSFR signaling and UPR activation

Supplemental data

PLASMA CELL DISORDERS

Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

Mateo Mejia Saldarriaga,Darren Pan,Caitlin Unkenholz,Tarek H. Mouhieddine,Juan Esteban Velez-Hernandez,Katherine Engles,Joshua A. Fein,Jorge Monge,Cara Rosenbaum,Roger Pearse,David Jayabalan,Christian Gordillo,Hei Ton Chan,Samuel Yamshon,Santiago Thibaud,Markus Mapara,Giorgio Inghirami,Suzanne Lentzsch,Ran Reshef,Adriana Rossi,Samir Parekh,Sundar Jagannath,Shambavi Richard,Ruben Niesvizky,Mark Bustoros

View Articletitled, Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

Supplemental data

Halting multiple myeloma with MALT1 inhibition: suppressing BCMA-induced NF-κB and inducing immunogenic cell death

Yao Yao,Mei Yuan,Min Shi,Wenyu Li,Yuqian Sha,Yan Zhang,Canli Yuan,Jianping Luo,Zhenyu Li,Chengcheng Liao,Kailin Xu,Mingshan Niu

View Articletitled, Halting multiple myeloma with MALT1 inhibition: suppressing BCMA-induced NF-κB and inducing immunogenic cell death

Supplemental data

THROMBOSIS AND HEMOSTASIS

Multimodal mechanisms of pathogenic variants in the signal peptide of FIX leading to hemophilia B
Clinical Trials & Observations

Meng Gao,Long Chen,Jinlong Yang,Shixia Dong,Qing Cao,Zihan Cui,Yanyan Dong,Hongli Liu,Yan Shen,Haiping Yang,Zhenyu Hao,Lei Zhang,Weikai Li,Jian-Ke Tie,Guomin Shen

View Articletitled, Multimodal mechanisms of pathogenic variants in the signal peptide of FIX leading to hemophilia B

Supplemental data

Deletion of pyruvate dehydrogenase kinases reduces susceptibility to deep vein thrombosis in mice

Gagan D. Flora,Madankumar Ghatge,Manasa K. Nayak,Tarun Barbhuyan,Mariia Kumskova,Anil K. Chauhan

View Articletitled, Deletion of pyruvate dehydrogenase kinases reduces susceptibility to deep vein thrombosis in mice

Supplemental data

Affimer reagents as tool molecules to modulate platelet GPVI-ligand interactions and specifically bind GPVI dimer

Rui-Gang Xu,Christian Tiede,Antonio N. Calabrese,Lih T. Cheah,Thomas L. Adams,Julia S. Gauer,Matthew S. Hindle,Beth A. Webb,Daisie M. Yates,Alexandre Slater,Cédric Duval,Khalid M. Naseem,Andrew B. Herr,Darren C. Tomlinson,Steve P. Watson,Robert A. S. Ariëns

View Articletitled, Affimer reagents as tool molecules to modulate platelet GPVI-ligand interactions and specifically bind GPVI dimer

Supplemental data

The combination of Asp519Val/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential

Yuto Nakajima,Akihisa Oda,Nemekhbayar Baatartsogt,Yuji Kashiwakura,Tsukasa Ohmori,Keiji Nogami

View Articletitled, The combination of Asp519Val/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential

Supplemental data

Mitoxantrone ameliorates ineffective erythropoiesis in a β-thalassemia intermedia mouse model

Haihang Zhang,Rui Liu,Zheng Fang,Ling Nie,Yanlin Ma,Fei Sun,Jingjing Mei,Zhiyin Song,Yelena Z. Ginzburg,Jing Liu,Huiyong Chen

View Articletitled, Mitoxantrone ameliorates ineffective erythropoiesis in a β-thalassemia intermedia mouse model

Supplemental data

TRANSPLANTATION

PTCy vs CNI–based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT

Juan Montoro,Maud Ngoya,Alexander Kulagin,Sebastian Giebel,Annoek E. C. Broers,Stefania Bramanti,Khalid Halahleh,Jose A. Pérez-Simón,Carlos Solano,Tulay Ozcelik,Didier Blaise,Jaime Sanz,Marta Henriques,Régis Peffault de Latour,Rodrigo Martino,Christof Scheid,Laura Fox,Tomasz Gromek,Manuel Jurado,Ioanna Sakellari,Gwendolyn Van Gorkom,Paola Matteucci,Arnon Nagler,Yener Koc,Bertram Glass

View Articletitled, PTCy vs CNI–based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT

Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry

Sara J. Schonfeld,Bryan Valcarcel,Christa L. Meyer,Bronwen E. Shaw,Rachel Phelan,J. Douglas Rizzo,Ann Brunson,Julianne J. P. Cooley,Renata Abrahão,Ted Wun,Shahinaz M. Gadalla,Eric Engels,Paul S. Albert,Rafeek Yusuf,Stephen R. Spellman,Rochelle E. Curtis,Jeffery J. Auletta,Lori Muffly,Theresa H. M. Keegan,Lindsay M. Morton

View Articletitled, Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry

Supplemental data

AMPK drives both glycolytic and oxidative metabolism in murine and human T cells during graft-versus-host disease

Archana Ramgopal,Erica L. Braverman,Lee-Kai Sun,Darlene Monlish,Christopher Wittmann,Felicia Kemp,Mengtao Qin,Manda J. Ramsey,Richard Cattley,William Hawse,Craig A. Byersdorfer

View Articletitled, AMPK drives both glycolytic and oxidative metabolism in murine and human T cells during graft-versus-host disease

Supplemental data

RESEARCH LETTERS

Cardiovascular and genetic determinants of platelet high responsiveness: results from the Gutenberg Health Study

Gaukhar Baidildinova,Vincent ten Cate,Marina Panova-Noeva,Bianca Dahlen,Alexander Gieswinkel,Saskia von Ungern-Sternberg,Steffen Rapp,Konstantin Strauch,Manfred E. Beutel,Norbert Pfeiffer,Karl J. Lackner,Thomas Münzel,Hugo ten Cate,Philipp S. Wild,Kerstin Jurk

View Articletitled, Cardiovascular and genetic determinants of platelet high responsiveness: results from the Gutenberg Health Study

Supplemental data

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

Esperanza Martín-Sánchez,Laura Blanco,Peter S. Kim,Kamlesh Bisht,Hongfang Wang,Helgi Van de Velde,Tomas Jelinek,Catia Simoes,Felipe Prosper,Jesus F. San Miguel,Ana Alfonso,Juan Bergua,Rebeca Rodríguez-Veiga,Susana Vives,David Martínez-Cuadrón,Pau Montesinos,Bruno Paiva,Aintzane Zabaleta

View Articletitled, Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

Supplemental data

CRISPR/Cas9-mediated gene disruption determines the roles of MITF and CITED2 in human mast cell differentiation

Jiezhen Mo,Fredrik Wermeling,Gunnar Nilsson,Joakim S. Dahlin

View Articletitled, CRISPR/Cas9-mediated gene disruption determines the roles of MITF and CITED2 in human mast cell differentiation

Supplemental data

Characterization of cases with the rare cytogenetic abnormality i(7)(p10) reveals an association with IDH2-mutated AML

Anna Stengel,Katharina Hörst,Constanze Kühn,Manja Meggendorfer,Wolfgang Kern,Torsten Haferlach,Claudia Haferlach

View Articletitled, Characterization of cases with the rare cytogenetic abnormality i(7)(p10) reveals an association with IDH2-mutated AML

Supplemental data

T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy

Lisa J. Martin,James B. Whitmore,Rhine R. Shen,Frank Neumann

View Articletitled, T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy

Supplemental data

Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas
Clinical Trials & Observations

Jonathan D. Bender,Sudarshawn Damodharan,Christian M. Capitini,Amy Moskop,Keri Toner,Anant Vatsayan,Julie-An Talano,Christina Baggott,Deborah Schiff,Emmanuel Katsanis,Arunkumar J. Modi,Troy C. Quigg,Sunil S. Raikar,Liora M. Schultz,Lauren Pommert

View Articletitled, Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas

Supplemental data

COMMENTARY

Thrombophilia management calculator

Iztok Hozo,Benjamin Djulbegovic

View Articletitled, Thrombophilia management calculator

Supplemental data

ERRATUM

Hason M, Mikulasova T, Machonova O, et al. M-CSFR/CSF1R signaling regulates myeloid fates in zebrafish via distinct action of its receptors and ligands. Blood Adv. 2022;6(5)1474-1488.

View Articletitled, Hason M, Mikulasova T, Machonova O, et al. M-CSFR/CSF1R signaling regulates myeloid fates in zebrafish via distinct action of its receptors and ligands. Blood Adv. 2022;6(5)1474-1488.

Supplemental data

Cover Image

Cover Image

Variation in the hydrophobic region of factor IX’s (FIX) signal peptide (L24P) leads to aberrant subcellular localization of FIX. The green fluorescence indicates the subcellular distribution of L24P variant. Sec61B-mcherry (red) is used as an ER marker. Nuclei (blue) are stained with DAPI (4′,6-diamidino-2-phenylindole). See the article by Gao et al.

All Issues

Advertisement intended for health care professionals

Email alerts

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read
Most Cited

Histiocytosis of the orbit and its association with KRAS mutations

NUP98 is rearranged in 5.0% of adult East Asian patients with AML

Addressing financial hardship in malignant hematology and hematopoietic cell transplant: a team approach

CT strain metrics allow for earlier diagnosis of bronchiolitis obliterans syndrome after hematopoietic cell transplant

Advertisement intended for health care professionals

Issue Archive

Table of Contents

INSIDE BLOOD ADVANCES

This differentiation block will not stand, man: ivosidenib for MDS Clinical Trials & Observations

ADVANCES VIEWPOINT

Need for consensus on primary end points and efficacy definitions in trials for adult acute lymphoblastic leukemia Clinical Trials & Observations

CLINICAL TRIALS AND OBSERVATIONS

Determinants of cognitive dysfunction in adults with sickle cell–related stroke or suspected neurological morbidity Clinical Trials & Observations

Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19 Clinical Trials & Observations

Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim Clinical Trials & Observations

Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome Clinical Trials & Observations

GENE THERAPY

HEALTH SERVICES AND OUTCOMES

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma Clinical Trials & Observations

Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma Clinical Trials & Observations

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

PLASMA CELL DISORDERS

THROMBOSIS AND HEMOSTASIS

Multimodal mechanisms of pathogenic variants in the signal peptide of FIX leading to hemophilia B Clinical Trials & Observations

TRANSPLANTATION

RESEARCH LETTERS

Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas Clinical Trials & Observations

COMMENTARY

ERRATUM

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

This differentiation block will not stand, man: ivosidenib for MDS
Clinical Trials & Observations

Need for consensus on primary end points and efficacy definitions in trials for adult acute lymphoblastic leukemia
Clinical Trials & Observations

Determinants of cognitive dysfunction in adults with sickle cell–related stroke or suspected neurological morbidity
Clinical Trials & Observations

Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19
Clinical Trials & Observations

Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim
Clinical Trials & Observations

Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
Clinical Trials & Observations

Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma
Clinical Trials & Observations

Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma
Clinical Trials & Observations

Multimodal mechanisms of pathogenic variants in the signal peptide of FIX leading to hemophilia B
Clinical Trials & Observations

Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas
Clinical Trials & Observations